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cAMP induces a protein-synthesis-dependent late phase of long-
term potentiation (LTP) at CA3–CA1 synapses in acute hippocampal
slices. Herein we report cAMP-mediated LTP and long-term de-
pression (LTD) at monosynaptic CA3–CA1 cell pairs in organo-
typic hippocampal slice cultures. After bath application of the
membrane-permeable cAMP analog adenosine 3*,5*-cyclic mono-
phosphorothioate, Sp isomer (Sp-cAMPS), synaptic transmission
was enhanced for at least 2 h. Consistent with previous findings,
the late phase of LTP requires activation of cAMP-dependent
protein kinase A and protein synthesis. There is also an early phase
of LTP induced by cAMP; the early phase depends on protein kinase
A but, in contrast to the later phase, does not require protein
synthesis. In addition, the cAMP-induced LTP is associated with a
reduction of paired-pulse facilitation, suggesting that presynaptic
modification may be involved. Furthermore, we found that Sp-
cAMPS induced LTD in slices pretreated with picrotoxin, a g-ami-
nobutyric acid type A (GABAA) receptor antagonist. This form of
LTD depends on protein synthesis and protein phosphatase(s) and
is accompanied by an increased ratio of failed synaptic transmis-
sion. These results suggest that GABAA receptors can modulate the
effect of cAMP on synaptic transmission and thus determine the
direction of synaptic plasticity.
Long-term potentiation (LTP) and long-term depression(LTD) are persistent and activity-dependent modifications in
synaptic efficacy that are thought to underlie some mechanisms
for memory (1). Considerable evidence has suggested the in-
volvement of the cAMP-signaling pathway and of cAMP-
dependent transcription in both forms of synaptic plasticity
(2–6). At least two phases of LTP have been reported in CA1 of
the hippocampus: an early phase that occurs immediately after
tetanus and a late phase that usually begins 2–3 h after induction.
There is general agreement that the early phase of LTP does not
require protein synthesis and that the late phase requires both
transcription and translation (3, 7). Stimuli that induce LTP can
result in a rise in cAMP level (8), activation of cAMP-dependent
protein kinase A (PKA) (9, 10), and phosphorylation of some
PKA substrates (11). Despite these correlative data and despite
the general agreement that the late phase of LTP requires cAMP
and activation of PKA (3, 4), there is no general agreement that
the early phase of LTP requires the cAMP pathway. Some lines
of pharmacological and genetic evidence suggest that the early
phase of LTP does not require the cAMP pathway (12–14);
however, another pharmacological study suggests that PKA is
required (15).
In this study, we investigated the cAMP-induced synaptic plas-
ticity at monosynaptic CA3–CA1 synapses by using organotypic
hippocampal slice cultures that retain hippocampal cytoarchitec-
ture and apparently develop additional synaptic connections from
CA3 to CA1 cells (16). We used the membrane-permeable
analog of cAMP, adenosine 39,59-cyclic monophosphorothioate,
Sp isomer (Sp-cAMPS), as an agent for inducing cAMP-
mediated synaptic plasticity because Sp-cAMPS can selectively
induce a protein-synthesis-dependent late phase of field LTP in
CA1 in acutely prepared hippocampal slices (3). At monosyn-
aptic CA3–CA1 synapses, in addition to a protein-synthesis-
dependent late phase of LTP, we observed an early phase of LTP
induced by Sp-cAMPS. This early phase of LTP requires PKA
but is independent of protein synthesis. We have also observed
a cAMP-mediated LTD in slices pretreated with picrotoxin, a
g-aminobutyric acid type A (GABAA) receptor antagonist. This
form of LTD can be blocked by the protein phosphatase
inhibitor calyculin A, suggesting a requirement for activation of
protein phosphatases. The protein synthesis inhibitor anisomy-
cin prevents the induction of this form of LTD, indicating a
dependence on protein synthesis.
Materials and Methods
Hippocampal slices were obtained from P7–P9 rats and plated
on membrane inserts (MilliCell-CM, from Millipore), as de-
scribed (17). After at least 14 days in culture, slices were
transferred to the recording chamber, which was mounted on an
upright Olympus BX50WI microscope. Slices in the recording
chamber were continuously perfused with oxygenated artificial
cerebrospinal f luid (ACSF) at 32°C for at least 30 min before
recording. ACSF contained 149 mM NaCl, 2.7 mM KCl, 2.8 mM
CaCl2, 2.0 mM MgCl2, 11.6 mM NaHCO3, 0.4 mM NaH2PO4,
and 5.6 mM glucose, adjusted to pH 7.4 with NaOH; the
osmolarity was adjusted to 320 milliosmolar with sucrose.
Two sharp electrodes filled with 1 M potassium methyl sulfate
(with a resistance of 80–100 MV) were placed in CA3 and CA1
regions, under a 310 water immersion lens. The electrode tips
were then inserted into CA3 and CA1 pyramidal cells by using
electrophysiological cues without visualization of individual
cells. Recordings of both pre- and postsynaptic responses were
made with an Axoclamp 2A (Axon Instruments, Foster City,
CA). Single action potentials were elicited in CA3 cells by
injection of depolarizing current pulses (10–15 ms, 0.4–0.6 nA).
Excitatory postsynaptic potentials (EPSPs) of a single CA1 cell
were evoked by single action potentials elicited in a synaptically
connected CA3 cell. The criteria for monosynaptic connections
between cell pairs included relatively brief (i.e., less than 3 ms)
and constant latencies, as described elsewhere (16, 18). The
membrane resistances of both pre- and postsynaptic cells were
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monitored during the experiments by injection of hyperpolariz-
ing current pulses (100 ms, 0.2 nA). Baseline responses were
recorded for at least 20 min before drug application. Paired-
pulse facilitation was measured by application of paired current
pulses (0.4 nA, 10 ms in duration at 50-ms intervals) to presyn-
aptic CA3 cells. The amount of paired-pulse facilitation was
expressed as the percent increase in the amplitude of the second
response relative to the first. Recordings were filtered at 3 kHz,
digitized at 10 kHz (TL-1, DMA Interface, Axon Instruments),
acquired with PCLAMP 6 (Axon Instruments), and analyzed
off-line with CLAMPFIT 8.1 (Axon Instruments) and Microcal
ORIGIN 6.0 (Microcal Software, Northampton, MA). Data were
presented as mean 6 SEM. An unpaired Student’s t test was used
to compare EPSP amplitudes measured in the control group with
those in drug-treated groups, and a paired Student’s t test was
used to compare responses obtained before and after drug
treatments in the same group. Differences were considered
significant at the level of P , 0.05 or P , 0.01, as indicated.
Sp-cAMPS (Calbiochem) and adenosine 39,59-cyclic mono-
phosphothioate, Rp isomer (Rp-cAMPS, Calbiochem) were
prepared as 10 mM stock solutions and stored at 220°C.
Anisomycin (Sigma) and calyculin A (Calbiochem) were pre-
pared as concentrated stock solutions in DMSO and then diluted
to a final concentrations of 20 mM and 1 mM, respectively (for
both, final concentration of DMSO was 0.1%), before applica-
tion. Picrotoxin was obtained from Sigma.
Results
Sp-cAMPS Induces LTP at Monosynaptic CA3–CA1 Cell Pairs. CA3–
CA1 cell pairs in stratum pyramidale of organotypic hippocam-
pal slice cultures were recorded simultaneously (Fig. 1A). We
tested these cell pairs for synaptic connection by passing a
depolarizing pulse that evoked an action potential in the CA3
cell. Monosynaptic EPSPs were then accepted based on the
criteria of brief (typically less than 3 ms) and constant latencies
after the peak of the presynaptic action potential (Fig. 1 A). Bath
application of Sp-cAMPS (50 mM, 15–20 min) facilitated syn-
aptic transmission at CA3–CA1 synapses (Fig. 1B). The increase
in amplitude of evoked EPSPs reached a plateau within 30 min
after treatment with Sp-cAMPS and lasted for at least 2 h (150 6
3%, n 5 5). Paired-pulse facilitation is a widely accepted index
of presynaptic function (19); this parameter decreased from 29%
under baseline conditions to 10–16% after exposure to Sp-
cAMPS (Fig. 2), suggesting that a presynaptic mechanism may
contribute to the cAMP-induced LTP.
The Late Phase of LTP Requires Protein Synthesis. Previous reports
showed that the expression of the late phase of LTP requires
protein synthesis (3, 20). We therefore tested whether the LTP
induced by Sp-cAMPS in our experimental conditions required
protein synthesis. Anisomycin (20 mM) was included in the
perfusion solution for 30 min before Sp-cAMPS was applied and
for at least 40 min after Sp-cAMPS had been washed out. We
found that LTP induced by Sp-cAMPS could be characterized by
two phases, one independent of protein synthesis and one
dependent on protein synthesis. In measurements of evoked
EPSP amplitude, the early phase (i.e., 40–60 min after Sp-
cAMPS treatment) of LTP was unaffected by anisomycin (130 6
5%, n 5 4), whereas the late phase (i.e., 100–120 min after
Sp-cAMPS application) of LTP was blocked (107 6 4%, n 5 4)
(Fig. 3 A and C).
cAMP-Induced LTP Is PKA-Dependent. To investigate whether both
early and late phases of LTP induced by Sp-cAMPS are medi-
ated through PKA, slices were treated with the PKA inhibitor
Rp-cAMPS (100 mM), for at least 30 min before and during
application of Sp-cAMPS. In the presence of Rp-cAMPS, both
early and late phases of LTP were blocked (114 6 3%, n 5 4; and
111 6 2%, n 5 4, respectively) (Fig. 3 B and C). These results
show that, under our conditions, the induction of cAMP-
mediated early and late phases of LTP requires activation of
PKA.
Effect of Sp-cAMPS on Spontaneous EPSPs. In addition to potenti-
ation of evoked EPSPs, we also observed increased spontaneous
activities in CA1 cells after application of Sp-cAMPS. The
average increases in amplitude of spontaneous EPSPs (sEPSPs)
during the early and late phases of LTP were 194 6 43% (n 5
Fig. 1. cAMP-induced long-term synaptic potentiation at a monosynaptic
CA3–CA1 cell pair in hippocampal slice cultures. (A) Paired recordings of
presynaptic and postsynaptic cells were obtained from CA3 and CA1 regions,
respectively, of a hippocampal slice culture. DG, dentate gyrus. A typical EPSP
of a CA1 cell could be evoked by an action potential elicited in a synaptically
connected CA3 cell. (B) Summary graph illustrating a long-lasting synaptic
enhancement of EPSP amplitude (measured as percentage of the baseline)
when Sp-cAMPS (50 mM, 15 min) was applied to the bath. Each point is the
average of five experiments. Error bars indicate 6 SEM.
Fig. 2. cAMP-induced LTP is associated with a reduction in paired-pulse
facilitation during both early (40–60 min after Sp-cAMPS) and late phases
(100–120 min after Sp-cAMPS). Each point is the average of three experiments.
Error bars indicate 6 SEM.









4) and 373 6 47% (n 5 4), respectively (Fig. 4A). The frequency
of sEPSPs increased significantly from 1.2 6 0.2 Hz (the
baseline, n 5 4) to 3.3 6 0.3 Hz (the early phase, n 5 4, P , 0.05)
and 8.1 6 3.2 Hz (the late phase, n 5 4, P , 0.05) (Fig. 4B). The
increases in amplitude of sEPSPs associated with Sp-cAMPS-
induced LTP were inhibited by Rp-cAMPS (Fig. 4C) and by
anisomycin (Fig. 4D).
Sp-cAMPS Induces LTD in the Presence of Picrotoxin. In one exper-
iment, we fortuitously impaled a presynaptic interneuron in the
CA3 area. The induced action potential evoked an inhibitory
postsynaptic potential in a CA1 cell. We then observed that
Sp-cAMPS decreased the amplitude of the evoked inhibitory
postsynaptic potential. This depression recovered within 1 h
after Sp-cAMPS was washed out with normal ACSF (data not
shown). This result drew our attention to involvement of inhib-
itory synaptic transmission in Sp-cAMPS-induced LTP and to
the modulation of GABAA receptors by phosphorylation (21,
22). We therefore examined the effect of Sp-cAMPS on synaptic
transmission in the presence of picrotoxin, a GABAA receptor
antagonist.
Slices were pretreated with 20–50 mM picrotoxin before
application of Sp-cAMPS. Under these conditions, Sp-cAMPS
no longer induced LTP; instead, a persistent LTD gradually
developed and reached the maximum depression about 60 min
after the treatment (to 57 6 2% of baseline EPSP, n 5 5; Fig.
5 A and D). In contrast, application of picrotoxin alone caused
little or no depression of synaptic transmission (87 6 4%, n 5 4;
Fig. 5D). During this form of LTD, single presynaptic action
potentials in CA3 cells led to 35% of failed EPSPs in CA1 cells,
compared with 4% during baseline recordings (Fig. 5B). This
result suggests that an increased failure rate may partially
account for LTD.
LTD Requires Activation of Protein Phosphatases and Protein Synthe-
sis. Several investigators have proposed that hippocampal LTD
involves activation of protein phosphatases (23, 24). We there-
fore tested whether the LTD induced by concurrent application
of Sp-cAMPS and picrotoxin was mediated through protein
phosphatases. Slices were pretreated with 1 mM calyculin A, an
inhibitor of protein phosphatases 1 and 2A, for 1 h before
application of Sp-cAMPS and picrotoxin. The results showed
modest facilitation in slices pretreated with calyculin A (119 6
2%, n 5 3), compared with the robust LTD in slices exposed to
Sp-cAMPS and picrotoxin but not exposed to calyculin A (57 6
2%, n 5 5, P , 0.01) (Fig. 5 A and D).
We also examined whether LTD induced by concurrent
application of Sp-cAMPS and picrotoxin required protein syn-
thesis. In these experiments, anisomycin was included in the
ACSF for 10 min before application of picrotoxin, during
perfusion of picrotoxin and Sp-cAMPS, and for 40 min after
picrotoxin and Sp-cAMPS had been washed out. In slices
pretreated with anisomycin, combined application of Sp-cAMPS
and picrotoxin did not induce LTD, either at the early stage (i.e.,
40–60 min after Sp-cAMPS treatment, 110 6 3%, n 5 5) or at
the late stage (i.e., 100–120 min after Sp-cAMPS treatment,
116 6 1%, n 5 5) (Fig. 5 C and D).
Discussion
There are two main findings in this study. First, two distinct
phases of cAMP-mediated LTP can be characterized at mono-
synaptic CA3–CA1 synapses by the requirement for protein
synthesis: a protein-synthesis-independent early phase of LTP
and a protein-synthesis-dependent late phase of LTP. Both
phases require activation of PKA. Second, a form of LTD can be
induced by cAMP in slices pretreated with a GABAA receptor
antagonist. This form of LTD requires protein synthesis and
activation of protein phosphatases. These results demonstrate an
important role of GABAA receptors in modulating and deter-
mining the direction of cAMP-induced synaptic plasticity.
Several reports have shown that cAMP can selectively induce
a late phase of LTP in CA1 of acute hippocampal slices (3, 4, 20).
The measurements made at monosynaptic CA3–CA1 synapses in
the present study reveal a protein-synthesis-independent early
phase (40–60 min) of cAMP-induced LTP. There is a general
agreement that a late phase of LTP (100–120 min) requires the
Fig. 3. Induction of cAMP-mediated LTP requires PKA and the late phase of
LTP depends on protein synthesis. (A) Application of anisomycin (20 mM)
blocked the late phase of Sp-cAMPS-induced LTP without affecting the early
phase. Data are the average of four experiments. (B) Sp-cAMPS (50 mM) could
not induce synaptic enhancement in slices treated with Rp-cAMPS (100 mM).
(C) Summary of the effect of Sp-cAMPS (Sp) on synaptic transmission in slices
treated with Rp-cAMPS (Rp) or anisomycin (aniso), compared with the control
(pseudo perfusion). Values are percent changes in amplitude of EPSP mea-
sured at the early phase (40–60 min after Sp) and the late phase (100–120 min
after Sp). *, P , 0.05; **, P , 0.01, compared with the respective control. (A–C)
Error bars indicate 6 SEM.
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activation of adenylyl cyclase and cAMP-dependent PKA. How-
ever, a role of PKA in an early phase of LTP has been confirmed
only recently (15). By using a broad range of inhibitors, combi-
nations of inhibitors, and direct methods for introducing inhib-
itors into the postsynaptic cell, Otmakhova et al. (15) reported
that inhibition of the cAMP pathway indeed decreased an early
phase of LTP. The early phase of cAMP-induced LTP observed
in the present study can be blocked by a PKA inhibitor, and this
result adds support to the notion that the PKA signaling pathway
participates in induction of the early phase of LTP.
LTD may have distinguishable phases that are analogous to
LTP. The form of LTD induced by our protocol, namely,
concurrent application of Sp-cAMPS and picrotoxin, develops
gradually and reaches the maximum depression 60 min after the
treatment. Although we did not directly address whether mul-
tiple phases of LTD could be induced by our protocol, the time
course of induction and the complete blockade of LTD by the
protein synthesis inhibitor anisomycin appear to suggest a late
phase of LTD induced selectively in our experimental condition.
In fact, a late phase protein-synthesis-dependent LTD in hip-
pocampal slice cultures has been reported (25). Nevertheless, we
cannot rule out the possibility that LTD induced by concurrent
application of Sp-cAMPS and picrotoxin may include an early
phase of LTD that requires protein synthesis, presumably locally
and within 30 min after the drug treatment (26–28).
Activation of the cAMP cascade enhances evoked and spon-
taneous release of neurotransmitter in Schafferycommissural
terminals in CA1 of acute hippocampal slices (29), as indicated
by a significant increase in frequency of miniature excitatory
postsynaptic currents. Quantal analysis of unitary synaptic trans-
mission between CA3–CA1 synapses also suggests that the
cAMP-induced late phase of LTP involve an increase in the
number of quanta released in response to a single presynaptic
action potential (20). Such an increase may be a consequence of
new release sites resulting from membrane insertion into a preex-
isting presynaptic terminal of new active zones that can synchro-
nously release transmitters (20). This hypothesis has been further
supported by the finding of Sp-cAMPS-induced increases in the
number of functional presynaptic terminals at dissociated CA3–
CA1 neuronal cultures (30). In the present study, at monosynaptic
CA3–CA1 synapses studied by intracellular recordings from single
CA3 and CA1 cells, the cAMP-induced LTP was associated with a
reduction of paired-pulse facilitation, which also supports the
notion that Sp-cAMPS induces LTP by increasing neurotransmitter
release from presynaptic terminals.
Although we interpret our results in terms of activation of an
intracellular PKA pathway by Sp-cAMPS, it remains possible that
extracellularly applied Sp-cAMPS or a metabolite may affect
synaptic transmission by acting extracellularly to activate or inhibit
adenosine receptors (31–36). This hypothesis is unlikely in view of
our observations that the PKA inhibitor Rp-cAMPS completely
blocked the induction of LTP by Sp-cAMPS, indicating that
Sp-cAMPS is acting intracellularly on the PKA pathway.
Our results also suggest that Sp-cAMPS may act on inhibitory
synaptic transmission in addition to excitatory synaptic trans-
mission. If Sp-cAMPS indeed inhibits GABAA receptors and
thus subsequently enhances synaptic transmission, one expects
no further facilitation of synaptic transmission induced by Sp-
cAMPS when the action of GABAA receptors is removed by
application of picrotoxin. As expected, in the presence of
Fig. 4. Effect of Sp-cAMPS on sEPSP. (A) Cumulative sEPSP amplitude distributions show that cAMP-mediated LTP is associated with significant increases in
amplitudes of sEPSPs recorded both during the early phase (40–60 min after Sp, shaded line) and during the late phase (100–120 min after Sp, thin line), compared
with the baseline (thick line). (B) Frequency of sEPSPs was increased during both early and late phases of LTP. *, P , 0.05, compared with the baseline. (C) No
significant increase in the amplitude of sEPSPs was observed when Rp-cAMPS (Rp, 100 mM) was coapplied with Sp-cAMPS (50 mM). (D) Anisomycin (aniso, 20 mM)
prevented the Sp-cAMPS-associated increase in the amplitude of sEPSPs. Error bars indicate 6 SEM.









picrotoxin, Sp-cAMPS no longer induced an early phase of LTP.
To our surprise, LTD was induced in this condition. Although
several reports have shown that blockade of GABAA receptor-
mediated transmission can attenuate neuronal firing and teta-
nus-induced LTP in hippocampus (37, 38), the induction of LTD
has not been reported in the presence of a GABAA receptor
antagonist. Our result shows that the early phase of cAMP-
mediated LTP requires the function of GABAA receptors.
Moreover, when the early phase of LTP was blocked, the late
phase of LTP was also prevented. This suggests that the early
phase of LTP may act to induce the late phase of LTP.
Recently, it was suggested that a reversible change in phos-
phorylation of the a-amino-3-hydroxy-5-methyl-4-isoxazolepro-
pionic acid (AMPA) receptor subunit GluR1 could contribute to
bidirectional synaptic plasticity at CA3–CA1 synapses (39).
Other evidence also suggests that activation of protein phospha-
tases favors the induction of LTD, whereas activation of protein
kinases such as PKA, CaMK (calcium calmodulin kinase)-II, or
CaMKIV promotes LTP (6, 40). Furthermore, modulations of
GABAA receptors by PKA and protein phosphatases can elim-
inate and enhance the inhibitory function of GABAA receptors,
respectively (21, 22). It is therefore possible that PKA-activated
phosphorylation of both GABAA and AMPA receptors can
subsequently inhibit activation of protein phosphatases, ensuring
that the direction of synaptic plasticity is primarily toward
potentiation. Likewise, dephosphorylation of GABAA receptors
by protein phosphatases in the presence of a GABAA receptor
antagonist may directly or indirectly facilitate dephosphoryla-
tion of PKA sites on GluR1, leading to LTD. Our results
apparently support the involvement of protein phosphatases in
LTD induced by concurrent application of Sp-cAMPS and
picrotoxin. Further studies will be needed to explore how
modulations of GABAA receptors by PKA and protein phos-
phatases in the presence and absence of a GABAA receptor
antagonist determine the direction of cAMP-induced synaptic
plasticity.
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